← Back to Search

Transdermal System

Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch

Phase 1
Waitlist Available
Research Sponsored by Noven Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new skin patch called HP-1050 to see if it causes any skin irritation or allergic reactions. The study involves healthy women.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitization Evaluation
Skin Irritation Evaluation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HP-1050 patchExperimental Treatment1 Intervention
HP-1050 and Xulane will be administered simultaneously.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Noven Pharmaceuticals, Inc.Lead Sponsor
8 Previous Clinical Trials
2,339 Total Patients Enrolled
~47 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top